Not much to report today, AJ got the clippers out and cut his hair off. Girls didn't mind at all, I told them on the way home and they didn't even react when we got home, which was good.
We didn't go for a longer walk today, its been raining and muggy.
AJ says that he can feel the PICC line and its annoying, I can only imagine. Unless we can hope for some miracle that they do it in Houston, then I think we have to wait another week before they do the port. Seton is supposed to call me to schedule it. I will call them Monday if I haven't heard anything.
He sweated more than ever last night, first we thought maybe it was due to new sleep meds - Restoril, but I looked up the side effects and it has about 15 of them, but not one says sweating.
Lymphoma does though, so its probably that. Its kind of a weird holding place right now, he has had the Chemo and his whites have gone down and we are just kind of trying to figure out every day if that is the worst he is going to feel in the whole cycle. But we will learn with time what ups and downs in this procedure is …
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...